Eli Lilly and Company (NYSE:LLY) Upgraded by Scotiabank to “Strong-Buy” Rating

Eli Lilly and Company (NYSE:LLY) was upgraded by research analysts at Scotiabank to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.

Several other equities analysts have also commented on the stock. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research report on Monday, August 11th. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Leerink Partnrs raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Monday. Guggenheim reaffirmed a “buy” rating and set a $948.00 target price on shares of Eli Lilly and Company in a report on Thursday, October 16th. Finally, Morgan Stanley upped their target price on Eli Lilly and Company from $1,090.00 to $1,171.00 and gave the company an “overweight” rating in a research report on Thursday. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $999.32.

Eli Lilly and Company Stock Up 0.4%

Shares of LLY stock opened at $1,022.00 on Wednesday. The stock’s fifty day moving average price is $820.93 and its 200 day moving average price is $779.85. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,032.95. The company has a market cap of $966.19 billion, a price-to-earnings ratio of 66.80, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s revenue was up 53.9% compared to the same quarter last year. During the same period last year, the business posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of LLY. Brighton Jones LLC grew its holdings in shares of Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC raised its position in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the period. Covestor Ltd lifted its stake in shares of Eli Lilly and Company by 24.9% in the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock valued at $352,000 after purchasing an additional 85 shares during the last quarter. Kaufman Rossin Wealth LLC purchased a new position in shares of Eli Lilly and Company during the 1st quarter worth $242,000. Finally, Opes Wealth Management LLC grew its holdings in shares of Eli Lilly and Company by 6.6% during the 1st quarter. Opes Wealth Management LLC now owns 337 shares of the company’s stock worth $278,000 after purchasing an additional 21 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.